Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus; principles of therapy and revised recommendations

[1]  D. Back,et al.  Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. , 2003, British journal of clinical pharmacology.

[2]  J. Porter,et al.  Twice weekly tuberculosis preventive therapy in HIV infection in Zambia , 1998, AIDS.

[3]  M. Narita,et al.  Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. , 1998, American journal of respiratory and critical care medicine.

[4]  C. Whitney,et al.  Risk factors for rifampin mono-resistant tuberculosis. , 1998, American journal of respiratory and critical care medicine.

[5]  W. El-Sadr,et al.  Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Feinberg,et al.  Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Vol. 47/No. RR-5. , 1998 .

[7]  R. Chaisson,et al.  Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection , 1998, The Lancet.

[8]  L. Haramati,et al.  Effect of HIV status on chest radiographic and CT findings in patients with tuberculosis. , 1997, Clinical radiology.

[9]  A. Li,et al.  Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. , 1997, Chemico-biological interactions.

[10]  M. Vjecha,et al.  A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. , 1997, The New England journal of medicine.

[11]  A. Rachlis,et al.  Reduced Plasma Concentrations of Antituberculosis Drugs in Patients with HIV Infection , 1997, Annals of Internal Medicine.

[12]  J P Matts,et al.  Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  W. El-Sadr,et al.  A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. , 1997, The New England journal of medicine.

[14]  K. Castro,et al.  A Nosocomial Outbreak of Multidrug-Resistant Tuberculosis , 1997, Annals of Internal Medicine.

[15]  F. Plummer,et al.  Isoniazid preventive therapy for tuberculosis in HIV‐1‐infected adults: results of a randomized controlled trial , 1997, AIDS.

[16]  R. Ridzon,et al.  Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. , 1997, American journal of respiratory and critical care medicine.

[17]  R. Klein,et al.  A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Hom,et al.  Site of disease and opportunistic infection predict survival in HIV‐associated tuberculosis , 1997, AIDS.

[19]  Y. Cao,et al.  Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. , 1997, American journal of respiratory and critical care medicine.

[20]  P. Kvale,et al.  Incidence of Tuberculosis in the United States among HIV-Infected Persons , 1997, Annals of Internal Medicine.

[21]  M. Felten,et al.  Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. , 1996, American journal of respiratory and critical care medicine.

[22]  W. El-Sadr,et al.  The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. , 1996, American journal of respiratory and critical care medicine.

[23]  J. Mcgowan,et al.  Clinical predictors of tuberculosis as a guide for a respiratory isolation policy. , 1996, American journal of respiratory and critical care medicine.

[24]  D. Gottlieb,et al.  Rifampin preventive therapy for tuberculosis in Boston's homeless. , 1996, American journal of respiratory and critical care medicine.

[25]  J. T. Crawford,et al.  A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. , 1996, JAMA.

[26]  T. Frieden,et al.  The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. , 1996, JAMA.

[27]  R. Chaisson,et al.  Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. , 1996, American journal of respiratory and critical care medicine.

[28]  D. Weissman,et al.  Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. , 1996, Journal of immunology.

[29]  R. Chaisson,et al.  Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. , 1996, The New England journal of medicine.

[30]  M. Vjecha,et al.  Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration. , 1996, American journal of respiratory and critical care medicine.

[31]  D. Vlahov,et al.  Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. , 1996, Archives of internal medicine.

[32]  R. Shafer,et al.  Predictors of survival in HIV‐infected tuberculosis patients , 1996, AIDS.

[33]  T. Perneger,et al.  Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years , 1995, BMJ.

[34]  K. D. de Cock,et al.  Autopsy‐proven causes of death in HIV‐infected patients treated for tuberculosis in Abidjan, Côte d'lvoire , 1995, AIDS.

[35]  K. Gallicano,et al.  Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. , 1995, Clinical Infectious Diseases.

[36]  K. D. de Cock,et al.  Two‐year follow‐up of persons with HIV‐1− and HIV‐2‐associated pulmonary tuberculosis treated with short‐course chemotherapy in West Africa , 1995, AIDS.

[37]  R. Chaisson,et al.  Eleven years of community-based directly observed therapy for tuberculosis. , 1995, JAMA.

[38]  A. Bloch,et al.  Essential components of a tuberculosis prevention and control program; Screening for tuberculosis and tuberculosis infection in high risk populations : recommendations of the Advisory Council for the Elimination of Tuberculosis , 1995 .

[39]  R. Wallace,,et al.  Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  T. Hooton,et al.  Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. , 1995, American journal of respiratory and critical care medicine.

[41]  K. Holmes,et al.  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  G. Rao,et al.  Paradoxical progression of tuberculous lesions during chemotherapy of central nervous system tuberculosis. Report of four cases. , 1995, Journal of neurosurgery.

[43]  P. Davidson.  Managing tuberculosis during pregnancy , 1995, The Lancet.

[44]  R. O'brien,et al.  Preventive therapy for tuberculosis in HIV infection: the promise and the reality. , 1995, AIDS.

[45]  Lewis D. Griffin,et al.  National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome. , 1995, Archives of internal medicine.

[46]  M. Dietrich,et al.  A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[47]  W. Rom,et al.  Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. , 1995, The Journal of clinical investigation.

[48]  P. Piot,et al.  Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. , 1995, New England Journal of Medicine.

[49]  K. D. de Cock,et al.  Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire , 1995, The Lancet.

[50]  P. Barnes,et al.  A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. , 1994, American journal of respiratory and critical care medicine.

[51]  M. Vjecha,et al.  Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans , 1994, The Lancet.

[52]  S. Natal,et al.  Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. , 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[53]  R. Chaisson,et al.  Effectiveness of supervised, intermittent therapy for tuberculosis in HIV‐infected patients , 1994, AIDS.

[54]  M. Lederman,et al.  Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. , 1994, Journal of acquired immune deficiency syndromes.

[55]  G. Schoolnik,et al.  The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. , 1994, The New England journal of medicine.

[56]  D Alland,et al.  Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. , 1994, The New England journal of medicine.

[57]  D. Cohn.  Treatment and prevention of tuberculosis in HIV-infected persons. , 1994, Infectious Disease Clinics of North America.

[58]  S. Weis,et al.  The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. , 1994, The New England journal of medicine.

[59]  D. Mitchison,et al.  The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. , 1993, The Journal of antimicrobial chemotherapy.

[60]  J. Pape,et al.  Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection , 1993, The Lancet.

[61]  M. Iseman,et al.  Malabsorption of antituberculosis medications by a patient with AIDS. , 1992, The New England journal of medicine.

[62]  T. Singh,et al.  Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Implications for the expansion of the AIDS case definition. , 1992, Archives of internal medicine.

[63]  K. D. de Cock,et al.  Tuberculosis and HIV infection in sub-Saharan Africa. , 1992, JAMA.

[64]  J. T. Crawford,et al.  Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. , 1992, JAMA.

[65]  J. T. Crawford,et al.  An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. , 1992, The New England journal of medicine.

[66]  G. Schoolnik,et al.  An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. , 1992, The New England journal of medicine.

[67]  R. Shafer,et al.  Extrapulmonary Tuberculosis in Patients with Human Immunodeficiency Virus Infection , 1991, Medicine.

[68]  P. Piot,et al.  Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. , 1991, The American review of respiratory disease.

[69]  R. Chaisson,et al.  Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[70]  J. Justement,et al.  Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms , 1990, The Journal of experimental medicine.

[71]  D. Snider,et al.  Epidemiology of tuberculosis in the United States. , 1989, Epidemiologic reviews.

[72]  A. Fauci,et al.  Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[73]  G. Nabel,et al.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Vermund,et al.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[75]  J. Justement,et al.  Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. , 1987, Science.

[76]  R. Chaisson,et al.  Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. , 1987, The American review of respiratory disease.

[77]  A. Fauci,et al.  Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. , 1987, JAMA.

[78]  G. Scott,et al.  Acute respiratory distress related to chemotherapy of advanced pulmonary tuberculosis: a study of two cases and review of the literature. , 1986, The Quarterly journal of medicine.

[79]  J. Ellner.  Suppressor adherent cells in human tuberculosis. , 1978, Journal of immunology.

[80]  Mark A. Miller,et al.  Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. , 1998, The Journal of infectious diseases.

[81]  P. Hopewell,et al.  Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. , 1998, American journal of respiratory and critical care medicine.

[82]  J. Musser,et al.  Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. , 1996, American journal of respiratory and critical care medicine.

[83]  A. Boobis,et al.  Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. , 1986, British journal of clinical pharmacology.